Herbrand Cathy
Bioethics. 2017 Jan;31(1):46-54. doi: 10.1111/bioe.12311.
In February 2015 the UK became the first country to legalise high-profile mitochondrial replacement techniques (MRTs), which involve the creation of offspring using genetic material from three individuals. The aim of these new cell reconstruction techniques is to prevent the transmission of maternally inherited mitochondrial disorders to biological offspring. During the UK debates, MRTs were often positioned as a straightforward and unique solution for the 'eradication' of mitochondrial disorders, enabling hundreds of women to have a healthy, biologically-related child. However, many questions regarding future applications and potential users remain. Drawing on a current qualitative study on reproductive choices in the context of mitochondrial disorders, this article illustrates how the potential limitations of MRTs have been obscured in public debates by contrasting the claims made about the future beneficiaries with insights from families affected by mitochondrial disorders and medical experts. The analysis illuminates the complex choices with which families and individuals affected by mitochondrial disorders are faced, which have thus far remained invisible. An argument is presented for improved information for the public as well as an intensification of critical empirical research around the complex and specific needs of future beneficiaries of new reproductive biotechnologies.
2015年2月,英国成为首个将备受瞩目的线粒体替代技术(MRTs)合法化的国家,该技术涉及利用来自三个人的遗传物质创造后代。这些新的细胞重建技术旨在防止母系遗传的线粒体疾病传给亲生孩子。在英国的辩论中,线粒体替代技术常被视为“根除”线粒体疾病的直接且独特的解决方案,能让数百名女性拥有一个健康的、有生物学血缘关系的孩子。然而,关于未来应用和潜在用户仍存在诸多问题。本文借鉴了一项关于线粒体疾病背景下生殖选择的定性研究,通过将有关未来受益者的说法与受线粒体疾病影响的家庭及医学专家的见解进行对比,阐述了线粒体替代技术的潜在局限性在公众辩论中是如何被掩盖的。分析揭示了受线粒体疾病影响的家庭和个人所面临的复杂选择,而这些选择至今仍未被关注。文章主张为公众提供更多信息,并围绕新生殖生物技术未来受益者的复杂且特殊需求加强关键实证研究。